All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Nivolumab/Ipilimumab Stands as the SOC for MSI-H/dMMR mCRC

April 23rd 2025

Heinz-Josef Lenz, MD, and Van Karlyle Morris, MD, discuss the significance of the FDA approval of nivolumab plus ipilimumab for MSI-H/dMMR mCRC.

Extended Adjuvant Pyrotinib Shows Promising Efficacy After Trastuzumab-Based Therapy in HER2+ Breast Cancer

April 23rd 2025

Pyrotinib led to high 2-year iDFS rates in the adjuvant setting following adjuvant trastuzumab-based treatment in HER2-positive breast cancer.

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC

April 23rd 2025

Aiwu Ruth He, MD, PhD, discusses data from the CheckMate 9DW trial that supported the FDA approval of frontline nivolumab plus ipilimumab for advanced HCC.

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study

April 23rd 2025

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Cultural Competency and Respect Are Crucial for Addressing Disparities in Cancer Care

April 23rd 2025

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

BCB-276 Earns FDA Breakthrough Therapy Nod for Pediatric Diffuse Intrinsic Pontine Glioma

April 23rd 2025

The FDA granted breakthrough therapy designation to BCB-276 for pediatric diffuse intrinsic pontine glioma.

First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC

April 23rd 2025

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

April 23rd 2025

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL

April 23rd 2025

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML

April 22nd 2025

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC

April 22nd 2025

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Responsible AI Use Ushers in a New Era of Oncology Practice and Patient Care

April 22nd 2025

Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.

Fox Chase Cancer Center Physicians Open New Trial For Patients With Colorectal Cancer That Has Spread to the Liver

April 22nd 2025

Physicians at Fox Chase Cancer Center have begun accepting patients for a new clinical trial looking at the effectiveness of a HAI pump along with standard chemotherapy.

Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS

April 22nd 2025

Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.

Health Canada Approves Pembrolizumab/Chemotherapy for Unresectable, Advanced or Metastatic Pleural Mesothelioma

April 22nd 2025

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

Oncodetect Test Is Now Available for MRD Detection in Solid Tumors

April 22nd 2025

The Oncodetect test is now available for use in molecular residual disease detection in patients with solid tumors.

Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’

April 22nd 2025

Reshma Mahtani, DO, highlights her experience as a leader in oncology and emphasizes the need to further uplift other women in the field.

Salvage ASCT Shows No Long-Term PFS or OS Benefit in Relapsed Myeloma

April 22nd 2025

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Early ESR1 Mutation Detection via ctDNA Monitoring Could Enhance Treatment Adaptation in HR+ Breast Cancer

April 21st 2025

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.